Eduardo

“Here we'll talk a little about why Brazil at this time has a very unique opportunity when you talk about minerals, mainly about critical minerals. Probably what I'm showing there is not new for anyone, but I think it's important we review again.”

“Following the Vizient contract effective January 1st, How much of your growth in 2026 do you think is attributable to this new volume of GPO versus organic growth in existing accounts?”

“Can you talk a little bit about the demand you're seeing for, I guess, the Wagovi pill and the brand products? How does that compare to, like, say, 3Q and 4Q of 25 heading into 1Q of 26?”

“I was hoping if I could, maybe I'll follow up briefly on the IGE. I'm curious if there's any significant biological differences in the IEEG readings compared to focal epilepsy that can make continuous improvements more challenging.”

“Just following up on the geographic atrophy trial, do you have any idea of what level of lesion growth inhibition you're targeting to consider that trial a success in that broad population?”